Dynavax Technologies Corporation
LSE: 0IDA.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Ryan Spencer
- Employees
- 405
- Headquarters
- EmeryVille, United States
- IPO year
- 2018
- Market cap
- $1.8B
- Website
- https://www.dynavax.com
Loading 0IDA…
Loading profile data…Frequently asked questions about 0IDA
What does Dynavax Technologies Corporation (0IDA.L) do?
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
Where does 0IDA.L trade?
Dynavax Technologies Corporation (0IDA.L) trades on the London Stock Exchange.
What sector is 0IDA.L in?
Dynavax Technologies Corporation (0IDA.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Dynavax Technologies Corporation?
Ryan Spencer is the chief executive officer of Dynavax Technologies Corporation (0IDA.L).
Where is Dynavax Technologies Corporation headquartered?
Dynavax Technologies Corporation is headquartered in United States.
Does 0IDA.L pay a dividend?
Dynavax Technologies Corporation (0IDA.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0IDA.L go public?
Dynavax Technologies Corporation (0IDA.L) completed its initial public offering in 2018.